Research programme: aurora kinase A inhibitors - Sunesis
Latest Information Update: 08 Jun 2008
At a glance
- Originator Sunesis Pharmaceuticals
- Mechanism of Action Aurora kinase A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Jun 2008 Discontinued for Cancer in USA (unspecified route)
- 26 Mar 2008 Early research in Cancer in USA (unspecified route)